Acute Myeloid Leukemia
Clinical research in acute myeloid leukemia focuses on RARA-positive disease subsets, including newly diagnosed and previously untreated patients. The sponsor’s studies examine targeted treatment strategies in biomarker-defined populations with an emphasis on response outcomes and hematologic remission.
- RARA-positive AML
- Biomarker-directed therapy
- Complete remission
Interest extends to combination regimens involving tamibarotene with other anti-leukemic therapies, reflecting a therapeutic focus on molecularly selected AML populations.
Myelodysplastic Syndrome
Studies in myelodysplastic syndrome address higher-risk disease and RARA-positive patient groups, particularly in newly diagnosed adults. The research program centers on improving disease control in patients with limited treatment options.
- Higher-risk MDS
- RARA-positive MDS
- Transfusion independence
Key therapeutic interest lies in epigenetic and differentiation-based approaches used alongside established myeloid malignancy treatments.
Targeted RARA-Directed Oncology
The sponsor’s research portfolio is concentrated on retinoic acid receptor alpha biology and biomarker-selected oncology. This includes investigation of selective RARα agonist activity in myeloid cancers and related treatment-resistant settings.
- RARA-positive malignancies
- Selective retinoid therapy
- Molecular patient selection
The therapeutic domain is centered on precision approaches for hematologic cancer subtypes defined by RARA expression.
Combination Regimens in Hematologic Malignancy
Research activity includes multi-agent treatment strategies for AML and MDS, with combinations built around tamibarotene, azacitidine, venetoclax, and daratumumab. These programs reflect interest in integrating targeted agents with established myeloid-directed therapies.
- Combination therapy
- Myeloid malignancies
- Response-focused treatment
The clinical emphasis remains on treatment-naive and higher-risk populations with RARA-positive disease.
